Enveric Biosciences 3/25/2024 Earnings Report

Enveric Biosciences EPS Results

• Actual EPS: -$21.90
• Consensus EPS: -$23.25
• Beat/Miss: Beat by +$1.35
• One Year Ago EPS: N/A

Enveric Biosciences Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Enveric Biosciences Announcement Details

• Date: 3/25/2024
• Time: N/A
• Conference Call Date: N/A
• Conference Call Time: N/A

Enveric Biosciences (NASDAQ:ENVB) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel psychedelic-based therapeutics for the treatment of psychiatric and neurological disorders. The company’s research platform leverages proprietary medicinal chemistry to design, synthesize and optimize molecules derived from established psychoactive compounds, with a goal of improving safety, efficacy and tolerability compared with traditional formulations.

Enveric’s preclinical pipeline features synthetic analogs of ibogaine, psilocybin and MDMA, each engineered to enhance therapeutic outcomes in conditions such as post-traumatic stress disorder, major depressive disorder and anxiety. In parallel with pharmacology studies, the company is advancing formulation development, toxicology evaluations and analytical methods to support regulatory submissions and clinical trial readiness.

The company emphasizes a robust regulatory strategy and plans to file investigational new drug (IND) applications in the United States and Canada. Enveric collaborates with academic institutions, contract research organizations and clinical advisors to validate its drug candidates in emerging psychiatric therapy paradigms, including adjunctive use alongside psychotherapy.

Enveric Biosciences trades on the NASDAQ under the ticker ENVB, following a corporate rebranding from FSD Pharma in October 2021 to reflect its exclusive focus on psychedelic medicine. The company is pursuing strategic partnerships and geographic expansion across North America and Europe to accelerate clinical development and future commercialization of its pipeline assets.